Important: The POPLINE website will retire on September 1, 2019. Click here to read about the transition.

Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting [letter]

Author: 
Kumarasamy N; Venkatesh KK; Devaleenal B; Palanivel V; Cecelia AJ
Source: 
Journal of Acquired Immune Deficiency Syndromes. 2007 Aug 15; 45(5):598-600.
Abstract: 

The World Health Organization recommends the use of generic nevirapine (NVP)/efavirenz (EFV)-based highly active antiretroviral therapy (HAART) regimens as first-line therapy in the management of HIV in resource-limited settings. Initiating NVP-based HAART at elevated CD4 cell counts can lead to liver toxicity. Short-term risk of liver toxicity has been reported in men with CD4 counts greater than 400 cells/mL and in women with CD4 counts greater than 250 cells/mL. Hence, clinicians are advised to monitor the results of liver chemistry tests closely in the first 18 weeks of therapy because of the potential to develop life-threatening hepatic events. Mocroft et al showed that initiating NVP therapy at elevated CD4 levels may be safe for use in antiretroviral-experienced patients. Little is known about short-term adverse consequences and clinical outcome at elevated CD4 cell counts in a resource-limited setting. (author's)

Language: 
Year: 
Region / Country: 
Document Number: 
320653
Add to my documents. Add to My Documents